- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
4 result(s) found for: Scarlet fever.
Displaying page 1 of 1.
EudraCT Number: 2018-000102-33 | Sponsor Protocol Number: 69HCL16_0079 | Start Date*: 2018-03-22 | |||||||||||
Sponsor Name:Hospices Civils de Lyon | |||||||||||||
Full Title: Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in children: a multicenter European randomized controlled trial | |||||||||||||
Medical condition: toxic shock syndrome | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Not Authorised) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005509-29 | Sponsor Protocol Number: 2013-841 | Start Date*: 2014-07-25 | |||||||||||
Sponsor Name:Hospices Civils de Lyon | |||||||||||||
Full Title: Efficacité des immunoglobulines humaines normales (IGHN) dans les chocs toxiques (staphylococciques et streptococciques) : étude de faisabilité pédiatrique. | |||||||||||||
Medical condition: toxic shock syndrome | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006161-18 | Sponsor Protocol Number: 115650 | Start Date*: 2014-09-25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A phase IIIA, randomized, observer-blind, controlled, multinational study to evaluate the safety and immunogenicity of GSK Biologicals' MMR vaccine (209762) (Priorix®) compared to Merck & Co., Inc.... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (Active immunization against measles, mumps and rubella diseases in healthy children, 12 to 15 months of age) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: EE (Completed) FI (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-005281-30 | Sponsor Protocol Number: DUR001-306 | Start Date*: 2016-11-03 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Allergan Ltd. | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Bacterial Skin and Sk... | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Acute bacterial skin and skin structure infection. For Cohort 5 (from birth to less than 3 months) also patients with sepsis are allowed. | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: LV (Prematurely Ended) LT (Prematurely Ended) ES (Prematurely Ended) BG (Completed) GR (Completed) PL (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
